RxSight, Inc.: insider trades · United States · SEC (Form 4)

About RxSight, Inc.

RxSight, Inc. is a U.S.-based ophthalmic medical device company listed on the Nasdaq market in the United States under ticker RXST. For French-speaking investors, the equity case is best understood as a focused premium-cataract story built around postoperative refractive customization. The company was originally founded in California in 1997 under the name Calhoun Vision, changed its name to RxSight in October 2016, and later reincorporated in Delaware in 2021. Its principal executive offices are in Aliso Viejo, California. RxSight’s business is centered almost entirely on its Light Adjustable Lens system, or LAL platform, paired with the Light Delivery Device (LDD) and related accessories. The core innovation is that the lens can be adjusted after cataract surgery, allowing physicians to fine-tune the patient’s vision once healing is underway. That differentiates RxSight from conventional intraocular lenses, which are selected and fixed before surgery. The company currently commercializes two lens variants, LAL and LAL+, with the latter designed to provide a modest extension of depth of focus. In commercial terms, RxSight offers an integrated workflow: implant, in-office light-treatment device, consumables, and a clinical ecosystem built around the adjustment process. From a competitive standpoint, RxSight occupies a specialized but attractive niche in premium cataract care. Management describes the system as the first and only commercially available IOL technology that can be adjusted after surgery. That uniqueness is the company’s main moat and supports premium positioning with surgeons and patients seeking more precise refractive outcomes. The trade-off is that adoption depends on surgeon training, practice workflow integration, and continued expansion of the installed base of LDD devices. As a result, RxSight’s opportunity is tied not just to lens sales, but also to procedure growth across its network of trained practices. Recent developments have been important for both commercial momentum and geographic expansion. In February 2026, the company said more than 300,000 LAL procedures had been performed since launch, the installed base of LDDs had reached 1,134, and regulatory approval had been received in Australia, broadening its international addressable market. RxSight also said FDA post-approval study results were accepted for publication in the Journal of Cataract & Refractive Surgery. The company continues to hold regulatory approvals across North America, Europe, Singapore, South Korea, and Australia. For investors, RxSight remains a commercial-stage medtech growth story: differentiated intellectual property, an expanding clinical base, and international optionality, but with execution risk still centered on sales force productivity, surgeon adoption, and operating leverage.